^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Nasopharyngeal Carcinoma
    Drug:Anniko (penpulimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

    Excerpt:
    ...Overall survival(OS)`Objective response rate (ORR)`Duration of response (DoR)`Disease control rate (DCR)`Adverse event (AE)`Maximum observed concentration (Cmax)`Anti-drug antibodies (ADA)`PD-L1 expression`Blood EBV level...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Immunother Cancer
    Title:

    804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy

    Published date:
    11/09/2020
    Excerpt:
    AK105-202 (NCT03866967) is a multicenter, single-arm, open-label study of penpulimab in metastatic NPC patients...Penpulimab demonstrated encouraging anti-tumor activity and favorable safety profile in pts with disease progression after ≥2 prior lines of therapy. A higher proportion of objective responses was observed in NPC pts with PD-L1–positive tumors receiving penpulimab than those with PD-L1–negative tumors.
    DOI:
    10.1136/jitc-2020-SITC2020.0804
    Trial ID:
    NCT03866967